| Identification | Back Directory | [Name]
4-(4-(4-Methylpiperazin-1-yl)piperidin-1-yl)aniline | [CAS]
959795-70-1 | [Synonyms]
Naquotinib intermediate
1,3-Propanediol,1-(7-piperidinyl)-
4-(4-(4-Methylpiperazin-1-yl)piperidin-1-yl)aniline
4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]benzenamine
Benzenamine, 4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-
4-[4-(4-Methyl-piperazin-1-yl)-piperidin-1-yl]-phenylamine | [Molecular Formula]
C16H26N4 | [MDL Number]
MFCD22493476 | [MOL File]
959795-70-1.mol | [Molecular Weight]
274.4 |
| Chemical Properties | Back Directory | [Boiling point ]
447.2±45.0 °C(Predicted) | [density ]
1.114±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C(protect from light) | [pka]
8.14±0.42(Predicted) | [Appearance]
Off-white to gray Solid |
| Hazard Information | Back Directory | [Uses]
4-(4-(4-Methylpiperazin-1-yl)piperidin-1-yl)aniline acts as a reagent in the preparation of Gilteritinib derivatives as inhibitors of FLT3-Axl. | [Synthesis]
GENERAL METHOD: 1-methyl-4-(1-(4-nitrophenyl)piperidin-4-yl)piperazine (2.18 g, 6.52 mmol) was dissolved in ethanol (50 mL) and 10% palladium carbon (wet basis, 53% water; 600 mg) was added. The reaction mixture was stirred at room temperature and 1 atm hydrogen atmosphere for 8 hours. Upon completion of the reaction, the insoluble material was removed by Celite filtration and the filtrate was concentrated under vacuum to afford 4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]aniline (1.96 g, 99%) as a light purple solid. | [References]
[1] Chemical and Pharmaceutical Bulletin, 2018, vol. 66, # 3, p. 251 - 262
[2] Patent: US2009/318441, 2009, A1. Location in patent: Page/Page column 45
[3] European Journal of Medicinal Chemistry, 2019, p. 690 - 709 |
|
| Company Name: |
Tetranov Biopharm
|
| Telephone: |
13526569071 |
| Website: |
http://www.leadmedpharm.com/index.html |
|